Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

In this study, intralesional triamcinolone acetonide was associated with eyebrow regrowth in some patients with frontal fibrosing alopecia.

In this study, researchers found that IGFBP‐rP1 levels were lower in individuals with androgenic alopecia compared to healthy controls, and subcutaneous injection of IGFBP‐rP1 showed potential in slowing hair loss progression in a mouse model by affecting the hair cycle transition.

This clinical study on fibrosing alopecia in a pattern distribution among a Latin American population reports no new results but addresses this specific condition in its demographic context.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This study presents a validated questionnaire, the FFA-QLI, which effectively assesses and differentiates the quality of life impact among patients with frontal fibrosing alopecia, showing greater sensitivity in identifying severe cases than the DLQI.

This study reports a case of frontal fibrosing alopecia associated with hepatitis C treatment involving interferon and ribavirin.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

This abstract describes frontal fibrosing alopecia, a type of cicatricial alopecia identified in post-menopausal women, and reports no new clinical findings.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This study found that intermittent treatment with FTI lonafarnib and sulforaphane may be a promising therapeutic approach for children with Hutchinson-Gilford progeria syndrome, as it improved the cellular phenotype.

This article reviews frontal fibrosing alopecia, exploring its characteristics, demographics, and associated conditions, and calls for controlled trials due to an increase in worldwide cases; it reports no new findings.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

This study found that photoacoustic imaging can effectively measure follicle density and angles, even when follicles are not visible to the eye, providing a promising alternative to traditional photographic examination.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

This study reports distinctive clinical, trichoscopic, and histopathological features of fibrosing alopecia in a pattern distribution among Chinese patients, suggesting possible racial differences compared to previous studies primarily involving Caucasians.

Early diagnosis and treatment can help manage fibrosing alopecia in older women.

This study found that dermal papilla cells from balding scalp follicles secrete significantly less insulin-like growth factor-1 and its binding proteins, suggesting a mechanism contributing to male pattern baldness.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This study found that women with female pattern hair loss had significantly lower serum IGF-1 levels than controls, suggesting a possible role for IGF-1 in this condition.

This article questions whether frontal fibrosing alopecia and fibrosing androgeneic patterned hair loss are overlapping conditions or stages of the same process, calling for further research to clarify their underlying factors.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

In this study, finasteride was found to significantly reduce DHT levels and affect spermatogenic markers in rats, while DA-9401 co-treatment indicated potential ameliorative effects.

This study found that iontophoresis with growth factor cocktail including fibroblast growth factor 5-short significantly increased hair density in patients with androgenetic alopecia over 24 weeks.

This study concluded that a 3% IGF-1 liposomal gel improved hair thickness and growth in hamsters without inducing significant hepatotoxicity or myelotoxicity, suggesting its potential as a safe hair-loss treatment.

This study found that injectable platelet-rich fibrin significantly improved hair growth and patient satisfaction as a cost-effective adjuvant treatment for androgenetic alopecia.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

In this study, a computer-aided imaging system accurately measured the width of balding areas in female pattern hair loss, correlating strongly with clinical staging severity.